国际肿瘤学杂志 ›› 2011, Vol. 38 ›› Issue (11): 861-863.

• 论著 • 上一篇    下一篇

放疗后生存时间5年以上局部晚期喉癌的预后因素分析

徐志渊, 林连兴, 李忆璇, 等   

  1. 515000 汕头市中心医院放疗科
  • 出版日期:2011-11-08 发布日期:2011-11-03
  • 通讯作者: 徐志渊, Email:xuzhiyuan8006@126.com E-mail:xuzhiyuan8006@126.com

Analysis of prognostic factors of local advanced glottic laryngeal cancer patients with beyond five years survival

XU  Zhi-Yuan, LIN  Lian-Xing, LI  Yi-Xuan, et al    

  • Online:2011-11-08 Published:2011-11-03

摘要: 目的 了解放疗后生存时间5年以上的局部晚期喉癌的临床特征,为晚期喉癌的临床治疗提供帮助。 方法 回顾性分析1999年1月至2005年8月收治的129例声门区喉癌患者的临床资料,按生存时间分为两组,46例为生存期大于5年组,83例为生存期小于5年组,比较两组的临床资料,并分析影响预后的因素。 结果  生存期大于5年组患者初治时淋巴结转移率较低、合并手术患者较多、治疗后完全缓解率较高,差异有统计学意义。多因素分析表明是否合并手术和放疗后喉和淋巴结肿瘤是否均达到完全缓解是预后的相关因素。 结论  局部晚期喉癌需要合理运用综合治疗,提高近期疗效,预防并发症,其确切证据有待大规模临床试验验证。

Abstract: Objective To evaluate the clinical features of local advanced glottic laryngeal cancer patients with beyond five years survival and to provide help for the treatment of advanced glottic laryngeal cancer patients. Methods The data of 129 cases of patients with local advanced glottic laryngeal cancer treated in our hospital from January 1991 to August 2005 were analyzed retrospectively. They were divided into two groups based on their survival time. Forty six patients with beyond five years survival were included in the first group and the other eighty three patients were in the second group. The clinical features were compared and factors associated with survival were identified. Results Compared with the group with under five years survival, the lymph node metastatic rate before treatment was lower, patients treated concurrently with operation were more, and complete remission rate after treatment were higher in the group with beyond five years survival. The differences between two groups had statistical significant.Cox regression analysis identified only operation and complete remission rate were independent prognostic factors. Conclusion For local advanced glottic laryngeal cancer,rational comprehensive treatment and complete remission after treatment and complications prevention are  important. But they need to be validated by the large-scale clinical trials.